RoboMed Secures Tens of Millions in New Funding Amid Capital Winter, Files for IPO

VCBeat has learned that Shenzhen ROBO Medical Technology Co., Ltd. (“ROBO Medical”) has recently completed a strategic financing round worth tens of millions of yuan. The round was led by Yuanchang Fund, under Fenglei Capital, with follow-on investment from existing shareholder Taikun Fund. MedBio Capital served as the exclusive financial advisor. The proceeds will be primarily used to accelerate the R&D and iteration of its intelligent surgical robot product portfolio, expand into global markets, and attract top-tier talent, marking a critical step forward in the company’s journey toward the domestic production of high-end medical equipment.

The successful financing of ROBO Medical underscores the capital market’s strong confidence in China’s original, innovative high-end medical equipment. Surgical robots represent a critical application scenario for the commercialization of medical AI. The ROBO team has not only overcome core technical bottlenecks in manipulating micro-diameter continuum flexible arms but also established a comprehensive product ecosystem, which constitutes the key rationale behind investor support.

It is reported that the financing will primarily be allocated to three major purposes:Core Technology Iteration and Product Line Expansion,Accelerate the performance optimization and clinical deployment of the existing core product, the EndoFaster (Suyibi) surgical robot, while advancing the research and development of the next-generation “EndoDreams” surgical robot;Capacity Expansion and Supply Chain Optimization,The technological revolution of the new era is reshaping the global economic landscape, with the entire industrial chain—including production, storage, transportation, and sales—related to emerging technologies being reconstructed under the influence of these advancements.Deepen Clinical Promotion,Expand clinical research collaborations with top-tier hospitals to accelerate product validation and market adoption.

As a leading domestically developed solution globally, EndoFaster, the digestive endoscopy surgical robot independently developed by ROBO Medical, has three major advantages:

• Subverting Tradition: From “One-Handed Blind Dissection” to “Bimanual Visualization”.The lead surgeon manipulates the endoscopic knife, while the EndoFaster robotic arm synchronously retracts tissue, ensuring blind spots such as the gastric fundus and cardia are fully exposed;

  
  

• Rapid Efficiency Boost: Halving Surgical Time.In comparative animal studies, EndoFaster-assisted ESD required only 18.8 minutes (versus 32.8 minutes with the conventional method), while significantly reducing the rate of muscularis propria injury. The learning curve for novice physicians was shortened by 60%, enabling them to perform the procedure independently in a shorter timeframe.

• Non-invasive Expansion: Early-stage Cancer Treatment.Flexible arm traction enables lesion exposure, 4-DOF master-slave control, and sub-millimeter operational precision.

The story of ROBO Medical began with a simple yet steadfast belief: to make more precise, safer, and more accessible medical technologies benefit more lives. A group of scientists and engineers, driven by ideals and deeply engaged in the fields of medical devices and robotics, came together. They understood that the integration of “robotics + healthcare” is not only a technological breakthrough but also a manifestation of dual care for both physicians and patients. Thus, ROBO Medical was established, committed to its mission of “empowering healthcare through technology to make it boundless.”

It is understood that ROBO Medical's future strategic layoutFocusing on three key directions:From the Digestive Tract to Multi-Specialty Coverage, leveraging the second-generation dual-channel flexible robotic arm system EndoDreams, the company will expand its product portfolio into new fields such as urology and gynecology;From Tertiary Hospitals to Primary Care Facilities, leveraging its cost advantage, the device will be rapidly rolled out to the national market, facilitating the implementation of the national public health initiative for “early detection and treatment of gastrointestinal cancers”;From China to the World, the company will be based in China and deeply cultivate the Chinese market, while steadily advancing registration processes and market expansion in key countries across Asia, Latin America, and Eastern Europe, thereby establishing a new paradigm for the global expansion of high-end medical equipment from China.